Additionally, boosting through cis activation allows the targeting of tumor-initiating CD20+ CSPG4+ melanoma cancer stem cells, which is supported by the clinical success using the anti-CD20 antibody Rituximab for treatment of melanoma (25, 26, 32–34). The gene discussed is CSPG4; the disease is neoplasm.